Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
115
resultados
Última actualización
09/12/2025 [07:07:00]
Resultados 75 a 100 de 115
Resumen de: US2025332220A1
The present invention relates to a method for treating and/or preventing pneumonia, including administering a therapeutically effective amount of cerebral dopamine neurotrophic factor (CDNF) to a subject in need thereof. The pneumonia is caused by infection of influenza A virus or severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Resumen de: WO2025225632A1
The purpose of the present invention is to provide an antiviral agent effective against COVID-19. The purpose can be achieved by (1) a polypeptide that contains an amino acid sequence selected from the group consisting of the amino acid sequence represented by SEQ ID NO: 1, the amino acid sequence represented by SEQ ID NO: 2, the amino acid sequence represented by SEQ ID NO: 3, the amino acid sequence represented by SEQ ID NO: 4, the amino acid sequence represented by SEQ ID NO: 5, the amino acid sequence represented by SEQ ID NO: 6, the amino acid sequence represented by SEQ ID NO: 7, and the amino acid sequence represented by SEQ ID NO: 8, or (2) a polypeptide that has antiviral activity against coronavirus, contains an amino acid sequence in which one amino acid is substituted in the amino acid sequence represented by SEQ ID NO: 1, the amino acid sequence represented by SEQ ID NO: 2, the amino acid sequence represented by SEQ ID NO: 3, the amino acid sequence represented by SEQ ID NO: 4, the amino acid sequence represented by SEQ ID NO: 5, the amino acid sequence represented by SEQ ID NO: 6, the amino acid sequence represented by SEQ ID NO: 7, or the amino acid sequence represented by SEQ ID NO: 8, said polypeptide having an O-glycoside-linked sugar chain.
Resumen de: US2025333809A1
Disclosed are oligonucleotide primers that hybridize specifically with any base sequence designed from the base sequences of the N gene, RNA-dependent RNA polymerase gene, M gene, and S gene of SARS-COV-2, a nucleic acid amplification method using said primers, a test method for SARS-COV-2 infection by detection of nucleic acid amplification, and a COVID-19 test kit.
Resumen de: EP4641196A1
Disclosed is a CRISPR/Cas based system for screening an RNA aptamer against a target protein, comprising: (i) a guide RNA comprising a recognition sequence and a nucleic acid aptamer random library having a predetermined length; (ii) a target sequence complementary to the recognition sequence of the guide RNA; (iii) a selection marker located downstream of the target sequence and comprising a basal promoter and a selection marker gene; (iv) a fusion protein comprising the target protein and a transcriptional activation module, wherein a binding of the target protein to an RNA aptamer of the nucleic acid aptamer random library results in recruitment of the transcriptional activation module to the selection marker; (v) a dCas protein specifically recognizing the target sequence under the guidance of the guide RNA; and (vi) a screening cell. Also disclosed is a method for screening an RNA aptamer against a target protein using the system provided herein and RNA aptamers against S1 protein of SARS-CoV-2 virus and applications thereof.
Resumen de: WO2024137381A1
Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies. In some aspects, the antibodies bind a BA.4 or BA.5 variant. In other aspects, the antibodies bind BQ1.1 and/or XBV.
Resumen de: EP4640230A1
An application of Shenling Baizhu in the preparation of a medicine for treating neuropsychiatric symptoms of recovered COVID-19 patients.
Resumen de: WO2024133564A1
: SARS-CoV-2 spike protein-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the SARS-CoV-2 spike protein-binding molecules.
Resumen de: ZA202500860B
Provided are a pharmaceutical composition for resisting infection with SARS-CoV-2 or a mutant thereof, and a combined drug thereof. To solve the problem of the lack of effective prevention and treatment drugs for infection with SARS-CoV-2 or a mutant virus thereof, provided are a recombinant protein vaccine and/or an adenovirus vaccine for preventing and/or treating an infection with SARS-CoV-2 or a mutant thereof, and in particular, provided are a nasal spray administration compound formulation containing active ingredients of two vaccines, i.e., a recombinant protein vaccine and an adenovirus vaccine, and a combination of the two vaccines for nasal spray administration, which can induce generation of strong antibody and cellular immune responses in vivo and block the binding of a protein S of SARS-CoV-2 to an ACE2 receptor of a host cell, thus enabling a host to resist coronavirus infection. Particularly, the present invention has good prevention and treatment effects on various mutant viruses.
Resumen de: LU601360B1
A Chinese medicine formula for COVID-19, comprising the following raw materials by weight ratio: 25 grams of siraitia grosvenorii flower, 10 grams to 20 grams of ligustrum lucidum, 5 grams to 10 grams of winter mulberry leaves, 8 grams to 15 grams of Chinese mahonia, 5 grams to 10 grams of Dizhu leaves, 5 grams to 10 grams of gardenia jasminoides, 3 grams to 8 grams of astragalus membranaceus, 3 grams to 8 grams of gentiana, 5 grams to 10 grams of ophiopogon japonicus, 2 grams to 6 grams of cassia twig, 3 grams to 8 grams of artemisia argyi leaves, and 10 grams to 15 grams of hairy holly. Based on the in-depth analysis of the pathogenesis characteristics of COVID-19, the invention achieves a comprehensive improvement of the symptoms of the COVID-19 by reasonable compatibility of a variety of Chinese medicinal materials; wherein, the combination of siraitia grosvenorii flower and ligustrum lucidum significantly improves the symptoms of dry throat and cough; winter mulberry leaves and Chinese mahonia can synergistically reduce fever quickly; the invention is suitable for various symptoms such as headache, fever, sore throat, chest tightness, cough (dry cough) caused by the COVID-19; generally, it turns from positive to negative in 3 to 4 days, and it takes 5 days to 8 days to eliminate all the symptoms mentioned hereinabove, depending on the physical condition of each person.
Resumen de: US12453717B1
The present disclosure relates to a method of reducing or arresting viral load in a subject infected with a coronavirus, the method comprising the step of administering to the subject a therapeutically effective amount of a viral protease inhibitor. In some embodiments, the subject is a human. In one embodiment, the coronavirus is SARS-CoV-19 and the viral protease inhibitor is frovatriptan (6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide.
Resumen de: KR20250153936A
본 발명은 페이퍼 멤브레인 기반 현장 진단용 DNA 또는 RNA 추출 키트에 관한 것으로, 측방 유동 분리 방식을 기반으로, 짧은 시간 내에 효율적으로 다양한 종류의 샘플들로부터 DNA 또는 RNA 추출이 가능한 DNA 또는 RNA 추출 디바이스로서, 표적 바이러스 검출을 위한 페이퍼 멤브레인 기반 현장용 DNA 또는 RNA 추출 플랫폼을 제공할 수 있다.
Resumen de: WO2025218020A1
Provided are a SARS-CoV-2 camelid-derived nanobody or an antigen-binding fragment thereof, and a composition thereof and a use thereof. The nanobody has at least 95% homology to SEQ ID NO: 1. Mutation engineering of the multivalent nanobody obtained by screening and purifying provides a method for rapidly generating an efficient virus neutralizing agent, such that viral escape mutants can be effectively controlled.
Resumen de: US2025326715A1
The invention provides novel compounds that are potent inhibitors of main protease (MPro) and pharmaceutical compositions and methods thereof for treating MPro-associated or mediated diseases and conditions, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).
Resumen de: US2025327039A1
Attenuate coronavirus species that are able to fully replicate and spread are proposed together with the methods of obtaining thereof. The proposed coronavirus species are intended to treat and prevent viral infections including all those caused by coronavirus species that affect humans as the COVID-19 caused by the SARS-CoV2. Compared with other treatment or vaccine alternatives, the availability of such attenuate coronavirus species does not require of significant distribution and production resources. Some of the embodiments of the invention involve the use of the attenuate coronavirus species in formulations or compositions that have to be approved as safe and effective for therapeutic use in specific territories by a valid regulatory agency as the Food and Drug Agency (FDA) in the United States.
Resumen de: US2025327038A1
Attenuate coronavirus species that are able to fully replicate and spread are proposed together with the methods of obtaining thereof. The proposed coronavirus species are intended to treat and prevent viral infections including all those caused by coronavirus species that affect humans as the COVID-19 caused by the SARS-CoV2. Compared with other treatment or vaccine alternatives, the availability of such attenuate coronavirus species does not require of significant distribution and production resources. Some of the embodiments of the invention involve the use of the attenuate coronavirus species in formulations or compositions that have to be approved as safe and effective for therapeutic use in specific territories by a valid regulatory agency as the Food and Drug Agency (FDA) in the United States.
Resumen de: US2025327142A1
Described herein are methods for the detection of a virus (e.g., SARS-CoV-2) RNA in dust, which can be used for continued environmental surveillance of the viral disease. Targeted monitoring of dust in high-concern buildings can complement broader population-level monitoring approaches. Additionally, a method for detection of a viral RNA in a dust sample is disclosed herein.
Resumen de: US2025325547A1
The present invention relates to a compound represented by formula (I), a salt thereof, a solvate thereof, or a prodrug thereof, and an anti-SARS-CoV-2 drug having the same:wherein R1, R2, and R3 are the same or different, and each of them is a hydrogen atom, a halogen atom, a substituted or unsubstituted C1-6-alkyl group, a substituted or unsubstituted C1-6-alkoxy group, or —N(Ra)(Rb) wherein Ra and Rb are the same or different, and each of them is a substituted or unsubstituted C1-10-alkyl group or a substituted or unsubstituted aryl group; or Ra and Rb, together with an adjacent nitrogen atom, may form a substituted or unsubstituted 5 to 7-membered ring,R4 is —N(Ra)(Rb) wherein Ra and Rb are the same or different, and each of them is a substituted or unsubstituted C1-10-alkyl group or a substituted or unsubstituted aryl group; or Ra and Rb, together with an adjacent nitrogen atom, may form a substituted or unsubstituted 5 to 7-membered ring,X is a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom, andthe hydroxyl group in the formula may be substituted with a protecting group.
Resumen de: US2025325652A1
Provided are an isolated polypeptide or an antigenic fragment thereof, an antibody binding to the isolated polypeptide or the antigenic fragment thereof, a composition including the isolated polypeptide or the antigenic fragment thereof, and an array including the isolated polypeptide or the antigenic fragment thereof. Further provided a method for detecting the presence of an antibody against SARS-COV-2 in a subject, a method for the prognosis of the subject infected with SARS-COV-2, a method for inducing an immune response against SARS-CoV-2 in a subject, and a method for preventing and/or treating a disease caused by SARS-COV-2 infection in a subject.
Resumen de: US2025325648A1
Described herein is a replicative Vesicular stomatitis virus (rVSV) comprising: a first Filoviridae glycoprotein comprising one or more influenza virus matrix 2 ectodomain peptide inserted into the first Filoviridae glycoprotein; and a second Filoviridae glycoprotein comprising a SARS-CoV2 Spike protein peptide inserted into the second Filoviridae glycoprotein, or a first Filoviridae glycoprotein comprising one or more influenza virus matrix 2 ectodomain peptide inserted into the first Filoviridae glycoprotein and a non-functional but immunogenic SARS-CoV2 Spike protein. The Spike protein or Spike protein peptide can be derived from different CoV-2 variants. The rVSV can be used as a Dual Action vaccine for vaccinating individuals simultaneously against both influenza virus and SARS CoV2 virus.
Resumen de: US2025325535A1
This invention provides a novel small-molecule allosteric protease inhibitor, 10-(4-methylphenyl)-7-phenyl-6,7,8,10-tetrahydro-5H-indeno1,2-bquinoline-9,11-dione, which exhibits the highest selectivity index (SI), and shows inhibition against several SARS-CoV-2 variants of concern (VOC) and multiple human coronaviruses including MERS-CoV, SARS-CoV, and HCoV-229E. Not only does it demonstrate antiviral potency against a wide spectrum of coronavirus strains and species, but it also shows drug synergism with nirmatrelvir, which could be used in combination therapy to not only treat coronavirus-caused infections and diseases, but also lower the risk of antiviral resistance.
Resumen de: US2025325653A1
Engineered SARS-CoV-2 variants having a combination of attenuating modifications, and their use as live-attenuated SARS-CoV-2 vaccines, are described. The recombinant genome of the live-attenuated SARS-CoV-2 encodes a modified spike (S) protein with a deletion of the polybasic site (ΔPRRA); encodes a modified non-structural protein 1 (Nsp1) with K164A and H165A substitutions; and includes a mutation that prevents expression of open reading frames (ORFs) 6, 7a, 7b and 8. The disclosed live-attenuated SARS-CoV-2 retain the capacity to infect and replicate in mammalian cells. Immunogenic compositions that include a live-attenuated SARS-CoV-2 and methods of eliciting an immune response against SARS-CoV-2 in a subject are also described. Further disclosed are a collection of reverse genetics plasmids that include the complement of the recombinant genome of the live-attenuated SARS-CoV-2 and methods of producing a live-attenuated SARS-CoV-2 using the reverse genetics plasmids.
Resumen de: US2025325672A1
The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), particularly the spike protein S1 of SARS-COV-2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by infection of SARS-COV-2 or for providing prophylaxis to a subject at risk of infection of SARS-COV-2.
Resumen de: US2025327052A1
The invention relates to recombinant mutated angiotensin converting enzyme 2 (ACE2) comprising one or more amino acid substitutions at amino acid positions T27, F28, K31, H34, Y41 and Q42 which have improved binding affinity to SARS-CoV-1 and/or SARS-CoV-2. It also relates to combinatorial mutant ACE2 comprising T27Y/K31 H/H34A, T27YZ K31 H/H134V and T27Y/K31 Y/H134V and the use of said mutant ACE2 for treating and preventing coronavirus infection.
Resumen de: AU2023395159A1
The present technology provides multivalent vaccine compositions and Tcell compositions comprising viral antigens and associated methods. In some embodiments, the viral antigens are SARS-CoV-2 antigens. The vaccine compositions and the T cell compositions may comprise each of a Spike (S) peptide, a VME1 (M) peptide, an NCAP (N) peptide, an ORF7a (7a) peptide, an ORF3a (3a) peptide, an ORF8 (8) peptide, and an Nsp6 peptide.
Nº publicación: US2025318951A1 16/10/2025
Solicitante:
OKS VLADIMIR [US]
OKS ANDREY [US]
Oks Vladimir,
Oks Andrey
Resumen de: US2025318951A1
A method for treating viral infections caused by viruses whose survival time depends on temperature (e.g., cold viruses, flu viruses, COVID-19, etc.) is based on administrating to a subject an effective amount of thermal energy transferred from a hotter liquid product to the colder subject using a predetermined combination of the temperature of the liquid product, the duration of time of supplying the liquid product, and the amount of the liquid product. This method of treatment inactivates viruses in the upper respiratory tract and gastrointestinal tract of the subject and enhances the response of the immune system, thereby preventing complications and accelerating the recovery of the infected subject.
BOPI
Sede Electrónica
